TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Open Access
- 1 March 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300552
Abstract
PURPOSE: Germline genetic testing (GT) is important for prostate cancer (PCA) management, clinical trial eligibility, and hereditary cancer risk. However, GT is underutilized and there is a shortage of genetic counselors. To address these gaps, a patient-driven, pretest genetic education webtool was designed and studied compared with traditional genetic counseling (GC) to inform strategies for expanding access to genetic services. METHODS: Technology-enhanced acceleration of germline evaluation for therapy (TARGET) was a multicenter, noninferiority, randomized trial (ClinicalTrials.gov identifier: NCT04447703 ) comparing a nine-module patient-driven genetic education webtool versus pretest GC. Participants completed surveys measuring decisional conflict, satisfaction, and attitudes toward GT at baseline, after pretest education/counseling, and after GT result disclosure. The primary end point was noninferiority in reducing decisional conflict between webtool and GC using the validated Decisional Conflict Scale. Mixed-effects regression modeling was used to compare decisional conflict between groups. Participants opting for GT received a 51-gene panel, with results delivered to participants and their providers. RESULTS: The analytic data set includes primary outcome data from 315 participants (GC [n = 162] and webtool [n = 153]). Mean difference in decisional conflict score changes between groups was –0.04 (one-sided 95% CI, –∞ to 2.54; P = .01), suggesting the patient-driven webtool was noninferior to GC. Overall, 145 (89.5%) GC and 120 (78.4%) in the webtool arm underwent GT, with pathogenic variants in 15.8% (8.7% in PCA genes). Satisfaction did not differ significantly between arms; knowledge of cancer genetics was higher but attitudes toward GT were less favorable in the webtool arm. CONCLUSION: The results of the TARGET study support the use of patient-driven digital webtools for expanding access to pretest genetic education for PCA GT. Further studies to optimize patient experience and evaluate them in diverse patient populations are warranted.Keywords
This publication has 36 references indexed in Scilit:
- Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testingContemporary Clinical Trials, 2022
- Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical PracticeClinical Genitourinary Cancer, 2022
- Barriers and facilitators of germline genetic evaluation for prostate cancerThe Prostate, 2021
- Clinical Implications of Germline Testing in Newly Diagnosed Prostate CancerEuropean Urology Oncology, 2021
- Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumClinical Genitourinary Cancer, 2019
- The past, present and future of service delivery in genetic counseling: Keeping up in the era of precision medicineAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2018
- Projecting the Supply and Demand for Certified Genetic Counselors: a Workforce StudyJournal of Genetic Counseling, 2017
- Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at DeathEuropean Urology, 2017
- Comments on ‘Current issues in non‐inferiority trials’ by Thomas R. Fleming, Statistics in Medicine, DOI: 10.1002/sim.2855Statistics in Medicine, 2007
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006